# US 2016/0251399 A1 · Peptidomimetic macrocycles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251399 A1
- Document ID: US20160251399A1
- Status: Published application
- Kind: A1
- Application number: 15/093,335
- Filed: 2016-04-07
- Published: 2016-09-01
- Earliest claimed: 2009-01-14
- Assignees: Aileron Therapeutics, Inc.
- Applicants: Aileron Therapeutics, Inc.
- Inventors: Huw M. Nash; David Allen Annis
- Web page: https://patentgrep.com/patent/US20160251399A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 31/16: for influenza or rhinoviruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/54: with at least one abnormal peptide link in the ring
- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K 14/005: from viruses
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2760/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A peptidomimetic macrocycle of the formula:
wherein:
each A, C, D, and E is independently a natural or non-natural amino acid;
each B is independently a natural or non-natural amino acid, amino acid analog, or
each R1 and R2 are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; each R3 is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R5;
each L is independently a macrocycle-forming linker of the formula -L1-L2-;
each L1 and L2 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R4—K—R4]n, each being optionally substituted with R5;
each R4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;
each K is independently O, S, SO, SO2, CO, CO2, or CONR3;
each R5 is independently halogen, alkyl, —OR6, —N(R6)2, —SR6, —SOR6, —SO2R6,—CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent;
each R6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
each R7 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R5, or part of a cyclic structure with a D residue;
each R8 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R5, or part of a cyclic structure with an E residue;
amino acids represented as $ are alpha-Me S5-pentenyl-alanine olefin amino acids;
each v and w are independently integers from 1-1000;
u is an integer from 1-10;
each x, y and z is independently integers from 0-10; and
each n is independently an integer from 1-5,
wherein the peptidomimetic macrocycle further comprises a triazole-containing crosslinker.

### Claim 25 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein the peptidomimetic macrocycle comprises a helix.

### Claim 26 (depends on 25)

The peptidomimetic macrocycle of claim 25, wherein the helix includes 1 to 5 turns.

### Claim 27 (depends on 25)

The peptidomimetic macrocycle of claim 25, wherein the length of the macrocycle-forming linker L is approximately 5 Å to 9 Å per turn of the helix.

### Claim 28 (depends on 25)

The peptidomimetic macrocycle of claim 25, wherein the length of the macrocycle-forming linker L is approximately 8 Å to 6 Å per turn of the helix.

### Claim 29 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid.

### Claim 30 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein x+y+z=2, 3, or 6.

### Claim 31 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein the peptidomimetic macrocycle comprises an alpha helix.

### Claim 32 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein R1 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-.

### Claim 33 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein R1 and R2 are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-.

### Claim 34 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein R1 and R2 are independently alkyl.

### Claim 35 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein R1 and R2 are methyl.

### Claim 36 (depends on 24)

The peptidomimetic macrocycle of claim 24, wherein the triazole-containing crosslinker stabilizes a secondary structure of the peptidomimetic macrocycle.
